**УДК [616.517:616.12-008.9]-085-035**

**MODERN APPROACHES TO TREATMENT OF PSORIASIS ASSOCIATED WITH CARDIO METABOLIC DISORDERS**

*Bilovol A.M., Tkachenko S.G.*

***Abstract.***

*The risk of cardio metabolic disorders is very high in psoriatic patients that associated with higher mortality. The aim of this study was to search of comorbidity psoriasis and cardio metabolic disorders for development of pathogenic treatment and to investigate effectiveness of metabolic treatment on dermatological and cardio metabolic indicators of patients suffering on psoriasis combined with cardio metabolic disorders. The study was conducted on two groups of patients. Different cardio metabolic violations were determined in 144 patients of 1 group and 69 patients of 2 group, respectively 78,6 % and 88,5 %. The patients of 1 group (183 examinee) were treated with traditional anti psoriatic therapy; patients of 2-nd group (78 examinee) were treated with metabolic therapy. The statistically significant difference between indexes in the dynamics of treatment of psoriasis first and second groups has not been detected (р>0,1). – 41 % and 44 % respectively. The more pronounced improvement of all cardio metabolic indicators was revealed in patients receiving metabolic therapy, particularly improvement of sleep (22,9 %), lowering of the blood pressure (59,7 %), decreasing of headaches (43,0 %) and reducing of cardiac dyspnea (22,9 %). The positive dynamics of key parameters of blood, reflecting lipid and carbohydrate metabolism, did not differ significantly between the groups. Using of metabolic therapy of psoriasis combined with cardio metabolic disorders makes possible to avoid medication for cardio metabolic comorbidity correction, or eliminate the use of already assigned symptomatic therapy.*

***Key words:*** *cardio metabolic disorders, co morbidity, psoriasis, therapy.*

**СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ ПСОРИАЗА, АССОЦИИРОВАННОГО С КАРДИОМЕТАБОЛИЧЕСКИМИ НАРУШЕНИЯМИ**

*Беловол А.Н., Ткаченко С.Г.*

***Резюме.***

*Риск кардиометаболических нарушений у больных псориазом очень высок, что ассоциируется также и с высокой смертностью. Целью данного исследования было изучение коморбидности псориаза и кардиометаболических нарушений для разработки патогенетического лечения и оценки влияния метаболической терапии на дерматологические и кардиометаболические показатели у больных псориазом, ассоциированным с кардиометаболическими нарушениями. Исследование проводили в двух группах больных псориазом. Различные кардиометаболические нарушения были выявлены у 144 пациентов 1 группы и 68 пациентов 2 группы, что составило 78,6 % и 88,5 % соответственно. Пациенты 1 группы (183 исследуемых) получали традиционное лечение псориаза, пациенты 2 группы (78 исследуемых) получали метаболическую терапию. Статистически значимой разницы динамки индексов в процессе лечения псориаза первой и второй групп выявлено не было (р>0,1). – 41 % и 44 % соответственно. Более выраженное улучшение по всем кардиометаболическим показателям было выявлено в группе пациентов, получавших метаболическую терапию, особенно улучшение сна (22,9 %), снижение артериального давления (59,7 %), уменьшение головных болей (43,0 %) и одышки (22,9 %). Позитивная динамика по ключевым параметрам крови, отражающим липидный и углеводный обмен, не отличалась статистически между группами. Использование метаболической терапии псориаза, ассоциированного с кардиометаболическими нарушениями, дает возможность избежать назначения медикаментозной коррекции сопутствующей патологии или сократить уже назначенную симптоматическую терапию.*

***Ключевые слова:*** *кардиометаболические нарушения, коморбидность, псориаз, терапия.*

**СУЧАСНІ ПІДХОДИ ДО ЛІКУВАННЯ ПСОРІАЗУ, АСОЦІЙОВАНОГО З КАРДІОМЕТАБОЛІЧНИМИ ПОРУШЕННЯМИ**

*Біловол А.М., Ткаченко С.Г.*

***Резюме.***

*Ризик кардіометаболічних порушень у хворих на псоріаз є досить високим, що асоціюється також і з високою смертністю. Ціллю даного дослідження було вивчення коморбідності псоріазу та кардіометаболічних порушень для розробки патогенетичного лікування та оцінювання впливу метаболічної терапії на дерматологічні та кардіометаболічні показники у хворих на псоріаз, асоційований з кардіометаболічними порушеннями. Дослідження проводили у двох групах хворих на псоріаз. Різні кардіометаболічні порушення були виявлені у 144 пацієнтів 1 групи та 68 пацієнтів 2 групи, що становило 78,6 % тa 88,5 % відповідно. Пацієнти 1 групи (183 хворих) отримали традиційне лікування псоріазу, пацієнти 2 групи (78 хворих) отримали метаболічну терапію. Статистичної різниці динаміки індексів в процесі лікування псоріазу в першій та другій групі виявлено не було (р>0,1). – 41 % и 44 % відповідно. Більш значуще покращення за всіма кардіометаболічними показниками було виявлене в групі пацієнтів, що отримали метаболічну терапію, особливо покращення сну (22,9 %), зниження артеріального тиску (59,7 %), зменшення головного болю (43,0 %) та задишки (22,9 %). Позитивна динаміка за ключовими параметрами крові, що відображують ліпідний та вуглеводний обмін, не відрізнялася статистично між групами. Використання метаболічної терапії псоріазу, асоційованого з кардіометаболічними порушеннями, робить можливим уникнути призначення медикаментозної корекції супутньої патології або скоротити вже призначену симптоматичну терапію.*

***Ключові слова:*** *кардіометаболічні порушення, коморбідність, псоріаз, терапія.*

**Introduction.** The question about comorbidity of psoriasis is very actual and socially significant. Treatment of dermatosis considering its comorbidity has been difficult and controversial problem. It is known, the risk of cardiovascular disorders is very high in psoriatic patients, that associated with higher mortality [9]. In study M.E. Roberts et al. [13] was shown, that the most frequent reasons of mortality among psoriatic patients were cardiovascular disorders (heart attack, cerebral and peripheral vascular disease). Similar results have been shown in a recent study [20]. According to current data, the rate of hypertension among patients with psoriasis is significantly higher than in the control group [15]. Recent studies have shown that psoriasis is independent risk factor for myocardial infarction and the patients with severe psoriasis have a greater risk of myocardial infarction [2,4].

The psoriatic arthropathy is accompanied by metabolic disorders, that manifest by deviation of protein metabolism with the development of hyperuricemia and podagra, carbohydrate metabolism (hyperglycemia, association with diabetes mellitus) and lipid metabolism (dyslipidemia, atherosclerosis, coronary heart disease, brain strokes, hypertension) [6,11]. Psoriatic patients have a higher prevalence of hyperlipidemia [10-11], abdominal obesity [5, 15], diabetes mellitus II type [14] and coronary heart disease [4]. These violations often form a metabolic syndrome. According to different authors, metabolic syndrome is detected much more frequently in patients with psoriasis, than in the control group [14, 17]. Mortality among psoriatic patients previously treated with drug therapy was 14,4 %, and those that did not receive antipsoriatic therapy was 10,5 % [9]. This fact demonstrates the urgency of psoriasis comorbidity analysis for choosing the optimal and safe treatment.

**The aim of this study** was to search of comorbidity psoriasis and cardio metabolic disorders for development of pathogenetic treatment and to investigate effectiveness of metabolic treatment of dermatological and cardio metabolic indicators of patients suffering on psoriasis combined with cardio metabolic disorders.

**The object and methods of the study.** The 261 psoriatic patients were examined and treated in an outpatient dermatologic city clinic № 5 in Kharkiv (Ukraine) during 2011-2014 yy. Treatment of patients with psoriasis was performed according by Ministry of Health of Ukraine Order № 312 from 05.08.09 "On approval of clinical protocols medical providing care for dermatovenereological patients." The conventional therapy included hyposensitization, microcirculatory and tranquilizing action drugs, adaptogens, immunomodulators, vitamins, topical keratolytics, corticosteroids, emollients. Considering high comorbidity of psoriasis and cardio metabolic disorders, we proposed combine therapy of psoriatic patients with using metabolic and cardioprotective drugs: infusions of Pentoxyphylline 0,5 mg in Ringer's lactated solution 200 ml every other day № 5, alternating with 1,5 % solution of Meglumine sodium succinate infusions 400 ml on alternate days № 5, intravenous injections of essential phospholipids 5 ml in 5 ml autoblood once a day № 10 and Magnesii sulfas intravenous injections 5 ml 25 % solution in 5 ml physiological saline once a day № 10. [7-8,12,16,19].

Standard examination of all patients have been provided: clinical blood and urine analysis, feces analysis on helminth eggs, RPR (rapid plasma reagin) by unified methods. The blood glucose level has been determined by the glucose oxidase method. [18]. The weight, height, waist and hips, systolic and diastolic blood pressure were measured. According dermatologist ʼs prescribing, the ultrasound examination, chemistry panel, expert advice of gastroenterologist, neurologist, endocrinologists, internists, etc. were provided. PASI and DLQI-Dermatology Life and Quality Index were calculated [1,3].

**Results of the study and its discussion.**

All patients have been divided on two groups (Table 1). Patients 1 group (183 examinee) were treated with traditional antipsoriatic therapy. Patients of 2 group (78 examinee) were treated with metabolic therapy. As a result of combined treatment, the clinical improvement of psoriasis occurred in varying degrees, that accompanied by decrease in desquamation, erythema and infiltration, regressing of psoriatic plaques, disappearance of koebnerization, significant decrease and disappearance of itching.

Table 1.- Comparative characteristic of groups.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Критерій | 1 group | | 2 group | |
| abs | % | abs | % |
| Number of patients | 183 |  | 78 |  |
| Male | 144 | 78,7 | 55 | 70,5 |
| Female | 39 | 21,3 | 23 | 29,5 |
| Average age (years) | 47±13,64 | | 51,3±13,91 | |
| Age to 39 years | 67 | 36,6 | 23 | 29,5 | |
| Age 40-60 years | 89 | 48,6 | 47 | 60,3 | |
| Age >60 years | 27 | 14,8 | 8 | 10,2 | |
| PASI<10 | 9 | 4,9 | 7 | 8,9 | |
| PASI 11-30 | 149 | 81,4 | 64 | 82,2 | |
| PASI>30 | 25 | 13,7 | 7 | 8,9 | |
| Average PASI | 23±7,6 | | 20±5,7 | | |
| DLQI 0-5 | 25 | 13,7 | 3 | 3,8 | |
| DLQI 6-10 | 98 | 53,6 | 30 | 38,5 | |
| DLQI 11-20 | 44 | 24,0 | 36 | 46,2 | |
| DLQI 21-30 | 16 | 8,7 | 9 | 11,5 | |
| Average DLQI | 7±2,9 | | 7±3,6 | | |

Average PASI decreased on 43 % (from 21±6,4 to 12±4,8).

There was no significant difference between patients 1-st and 2-nd group, reducing of clinical index was 41 % and 44 % correspondingly. Also the impact of psoriasis on quality of patients life was reduced and specific index is increased of 2 points after 10 days of treatment in both study groups (Figure 1).

Figure 1. Dynamics of PASI and DIQL in process of treatment of patients with psoriasis

The statistically significant difference between indexes in the dynamics of treatment of psoriasis first and second groups has not been detected (р>0,1).

Different cardio metabolic violations were determined in 144 patients of 1 group and 69 patients of 2 group, respectively 78,6 % and 88,5 %. The dynamics of cardiometabolic disorders observed by the main subjective and objective indicators that were controlled on the 1-st and 11-th days of traditional or metabolic therapy for psoriasis.

The positive dynamics was registered among all studied parameters in both groups of patients. Thus, the sleep disturbance were registered in 139 patients with psoriasis, while improving of sleep was detected in 60.4% of patients first group and 83.3% of the second group after treatment. (Figure 2).

Figure 2. The distribution of positive dynamics of cardio metabolic indicators after the traditional and metabolic treatment of psoriasis.

Increased blood pressure were registered at 107 psoriatic patients before therapy, improvement after treatment were observed in 40.3% of I group patients and in 100% of patients of II group. 120 patients complained of headache, while 51.9% improvement was registered in I group, and 94.9% in II group. We noted the cardiac dyspnea in 66 psoriatic patients, and registered reducing of this indicator in 55,3 % patients of 1-st group and 76,2 % patients of 2-nd group. The lipid and carbohydrate metabolism deviations were found in 49 patients 1-st group and 46 patients 2-nd group. The positive dynamics of these indicators in the 1 group was 73,1 % and 64,5 % respectively, in 2 group – 78,3 % and 66,7 %. The more pronounced improvement of all cardio metabolic indicators was revealed in patients receiving metabolic therapy, particularly improvement of sleep (22,9 %), lowering of the blood pressure (59,7 %), decreasing of headaches (43,0 %) and reducing of dyspnea (22,9 %). The positive dynamics of key parameters of blood, reflecting lipid and carbohydrate metabolism, did not differ significantly between the groups.

**Conclusions.** Thus, our study have shown comparable efficiency of metabolic and conventional therapy of psoriasis. At the same time, efficiency of correction of cardio metabolic disorders in comorbidity with psoriasis cases, was significantly higher in group treated with metabolic therapy. Using of metabolic therapy of psoriasis combined with cardio metabolic disorders makes possible to avoid medication for cardio metabolic comorbidity correction, or eliminate the use of already assigned symptomatic therapy. This is especially true for the use of antihypertensive drugs, because they are known risk factor for exacerbation of psoriasis and formation of the so-called "drug induced psoriasis".

**References**

1. Camisa C. Handbook of Psoriasis. 2. Ed. Oxford: Blackwell, 2004.;58.
2. Choi H.K., Rahman M.M., Kopec J.A., et al. Risk of myocardial infarction in patients with psoriatic arthritis // Arthr.Reum. – Abstract. – 2007. – Vol. 56, № 9. – P.799
3. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clinical and Experimental Derm 1994.- №19.-210-216.
4. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis // JAMA. – 2006.– Vol. 296, № 14. – P.1735-1741.
5. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management // Arch. Dermatol. – 2005. – Vol. 141, № 12. – P.1527-1534
6. Kimhi O. et al. Prevalence and risk factors of atherosclerosis in pathients with psoriatic arthritis. // Ann. Rheum. Dis. — 2006. — Vol. 65 (Suppl. 11). — P. 214.
7. Kobelyatsky Y. Y. et all. Effectiveness of Latren in treatment of ischemic disease of lower extremities associated with cardiac pathology //Consilium medicum Ukraina.-№7.-2009.-P. 29-32
8. Kostyanova E.N. The role of hypoxic changes and endogenous intoxication in the pathogenesis of psoriasis and their correction by Reamberin // Abstract diss. … c.m.s..-М., 2005-41p.;
9. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients // Eur. J. Epidemiol. – 2004. – Vol. 19, № 3. –P.225-230.
10. Mallbris L., Granath F., Hamsten A., et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease // J.Am. Acad. Dermatol. – 2006. – Vol. 54, № 4. – P.614-621
11. Mallbris L., Ritchlin C.T., Stahle M. Metabolic disoders in psoriasis and psoriatic arthritis. // Curr. Rheumatol. Rep. — 2006. — Vol. 8 (5). — P. 355-363.
12. Mavrov G.І., Sarian О.І. Risk factors of cardiovascular diseases of patients of psoriasis vulgaris //Dermatology and Venereology.-№3(57).-2012.-P.58-65
13. Roberts M.E., Wright V., Hill A.G.S., Mehra A.C. Psoriatic arthritis // Ann. Rheum. Dis. – 1976. – Vol. 35, № 3. –P.206-212.
14. Sapiro J., Kohen A., David M., et al. Association between psoriasis, diabetes mellitus and artherosclerosis. A case control study. // 1st World Psoriasis and psoriatic arthritis conference 2006, Stockholm, Abstract. — Stockholm, 2006. — P. 53.
15. Setty R.S., Quereshi A.A., Husni M.E., et al. Adyposity, smoking and the risk of psoriasis in women and implicacion on psoriatic arthritis – nurses health study II // Arthritis Rheum.– 2007. – Vol. 56(Suppl. 9). – P.799.
16. Shylov А.M. et all. Metabolic syndrome and and magnesium deficiency: the course and treatment //Doctor.-№ 9.-2008.-P.2-4
17. Sommer D.M., Jenisch S., Suchan M., et al. Increased prevalence of metabolic syndrome in patients with moderate to severe psoriasis // Arch. Dermatol. Res. – 2006. – Vol. 298, № 7. – P.321-328
18. Tietz N.W. Textbook of clinical chtmistry, 2nd ed., W.B.Saunders company, Philadelphia,1994, p.680
19. Tkachova M.Y., Yemelianov A.V., Krivoruchko M.E. The role of essentials phospholipids in treatment and prevention of metabolic syndrome // Health of Ukraine.-№ 23(234).-2013.-P.30-31
20. Wong K., Gladman D.D., Husted J., et al. Mortality stadies in psoriatic arthritis // Arthr. Reum. – 1997. – Vol. 40, №10. – P.1868-1872

**Author's data**

1. Bilovol Alla Mikolayevna.

Kharkiv National medical university, Kharkiv, Ukraine

61022, Kharkiv, avenue Lenina-4

22alla66@mail.ru, +38(057)706 31 99.

The Head of dermatology, venereology and medical cosmetology department, professor.

2. Tkachenko Svitlana Gennadiyevna

Kharkiv National medical university, Kharkiv, Ukraine

61022, Kharkiv, avenue Lenina-4

svetmail@mail.ru, +38(067)122 37 03

The docent of dermatology, venereology and medical cosmetology department